<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55419">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010632</url>
  </required_header>
  <id_info>
    <org_study_id>PDPK-CLO-2013</org_study_id>
    <nct_id>NCT02010632</nct_id>
  </id_info>
  <brief_title>Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products</brief_title>
  <official_title>Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products in Thai Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <authority>Thailand: Khon Kaen University Ethics Committee for Human Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacodynamic effect of clopidogrel on the
      platelet inhibition and the pharmacokinetic profiles of clopidogrel carboxylic acid
      metabolite between generic and reference clopidogrel products in Thai healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet aggregation (ex vivo) were measured by using  Whole blood impedence aggregometry
      (Chrono-log®) and VerifyNow® P2Y12 assay. Plasma concentration of clopidogrel carboxylic
      acid metabolite were measured by High performance liquid chromatography (HPLC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Pharmacodynamic effect: The platelet inhibition effect of clopidogrel at the various times on day 7 (0-24 hours) (at steady state)</measure>
    <time_frame>Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles: Area Under the Concentration-Time Curve (AUC 0-24)</measure>
    <time_frame>Blood collection at 0 (before dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles: The Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Blood collection at 0 (before dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profiles: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Blood collection at 0 (before dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Antiplatelet Agents</condition>
  <arm_group>
    <arm_group_label>Generic clopidogrel product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apolets® 75 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Original clopidogrel product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plavix® 75mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic clopidogrel product Apolets®</intervention_name>
    <description>Clopidogrel 75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</description>
    <arm_group_label>Generic clopidogrel product</arm_group_label>
    <other_name>Apolets®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Original clopidogrel product Plavix®</intervention_name>
    <description>Clopidogrel  75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7</description>
    <arm_group_label>Original clopidogrel product</arm_group_label>
    <other_name>Plavix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 45 years

          -  Body mass index between 18-25 kg/m2

          -  No clinically significant abnormalities, as confirmed on medical history; detailed
             physical examination; clinical laboratory analysis (blood hematology, biochemistry,
             prothrombin time, bleeding time, and urinalysis)

        Exclusion Criteria:

          -  An allergy to any drug; and/or a history of drug and/or alcohol abuse.

          -  Subjects who had donated blood within 3 months prior to the start of this study or
             had participated in another investigational drug study within 3 months prior to the
             start of this study

          -  Participating subjects were instructed to abstain from the use of any drugs for at
             least 2 weeks before and throughout the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wichittra Tassaneeyakul, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Somsak Tiamkao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sirimas Kanjanawart, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kutcharin Phunikhom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nontaya Nakkam, B.Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thanawat Kaewkamsorn, M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wichittra Tassaneeyakul, Ph.D.</last_name>
    <phone>+66-43-348397</phone>
    <email>wichitt@kku.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Somsak Tiamkao, MD</last_name>
    <phone>+66-43-363-665</phone>
    <email>somtia@kku.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khonkaen</city>
        <state>Khon Kaen</state>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wichittra Tassaneeyakul, Ph.D.</last_name>
      <phone>6643348397</phone>
      <email>wichitt@kku.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Nontaya Nakkam, B.Pharm</last_name>
      <phone>66862642540</phone>
      <email>nonna_na@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wichittra Tassaneeyakul, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Wichittra Tassaneeyakul</investigator_full_name>
    <investigator_title>Professor Dr. Wichittra Tassaneeyakul, Departments of Pharmacology, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Platelet inhibition</keyword>
  <keyword>Platelet aggregation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
